| Autor: |
Somonova OV, Madzhuga AV, Elizarova AL, Zubrikhina GN |
| Jazyk: |
ruština |
| Zdroj: |
Klinicheskaia laboratornaia diagnostika [Klin Lab Diagn] 2008 Nov (11), pp. 24, 33-4. |
| Abstrakt: |
Low molecular-weight heparins (clexan, fraxiparin, fragmin) were used in cancer patients to prevent hemostatic system disorders and related complications. The adequacy and safety of therapy were assessed measuring plasma anti-Xa activity in 239 patients. When the prophylactic doses of the low molecular-weight heparins clexan, fraxiparin, and fragmin were given, their anticoagulative effect was similar as judged from anti-Xa activity. Clexan exhibited the maximum anti-Xa activity when the therapeutic doses of the low molecular-weight heparins were used. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
